Mantle Cell Lymphoma in the Thyroid: A Rare Presentation.

Case Rep Pathol

Division of Endocrinology, University of Massachusetts Medical School, 55 Lake Avenue N., Worcester, MA 01655, USA.

Published: December 2017

Background: While 2% of all extranodal Non-Hodgkin Lymphomas present in the thyroid, there exists insufficient data to describe the incidence of mantle cell lymphoma in the thyroid. A case series of 1400 patients revealed that <1% of thyroid lymphomas may be MCL; hence better understanding of the disease course is essential.

Patient Findings: A 65-year-old female was referred for a multinodular goiter. Multiple fine needle aspirations from the dominant right nodule were consistent with Hashimoto's thyroiditis and flow cytometry was negative. Due to progressing dysphagia, she underwent total thyroidectomy.

Summary: Pathology revealed MCL with mantle zone growth pattern in the right thyroid. Flow cytometry showed monoclonal B cells comprising 9% of total cells. The Ki-67 index was 10%. She was diagnosed as having stage IIE MCL and offered conservative management by medical oncology, given that she had no B symptoms.

Conclusion: Though chemotherapy is the treatment of choice in MCL, a subset of patients with low-grade disease may be observed. As in our patient, mantle zone growth pattern and a Ki-67 index < 10% suggest a favorable prognosis. A diagnosis of primary MCL in the thyroid remains rare and staging modalities as well as treatment options continue to evolve.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757112PMC
http://dx.doi.org/10.1155/2017/6749801DOI Listing

Publication Analysis

Top Keywords

mantle cell
8
cell lymphoma
8
lymphoma thyroid
8
thyroid rare
4
rare presentation
4
presentation background
4
background extranodal
4
extranodal non-hodgkin
4
non-hodgkin lymphomas
4
lymphomas thyroid
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!